|
|
|
|
|
|
Sponsors and Collaborators: |
Pfizer Sanofi-Aventis |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00143338 |
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
Condition | Intervention | Phase |
Diabetes Mellitus, Type 2 |
Drug: Inhaled insulin |
Phase II |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Insulin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 2 Diabetes Mellitus. |
Estimated Enrollment: | 20 |
Study Start Date: | November 2004 |
Study Completion Date: | December 2006 |
Ages Eligible for Study: | 30 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |||||
Pfizer Investigational Site | |||||
Fresno, California, United States | |||||
United States, Texas | |||||
Pfizer Investigational Site | |||||
San Antonio, Texas, United States |
Pfizer |
Sanofi-Aventis |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Link to ClinicalStudyResults.org Posting: 
  |
Study ID Numbers: | A2171053 |
First Received: | August 31, 2005 |
Last Updated: | February 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00143338 |
Health Authority: | United States: Food and Drug Administration |
|
|
|